Across TCGA pan-cancer cohorts, NACAP5 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of NACAP5’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NACAP5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NACAP5 is over-expressed in tumor.
HNSC and LIHC are the cancer types where NACAP5 tumor–normal differential expression is most reproducible.